On July 16, 2025, Tazeen Ahmad, an analyst at B of A Securities, maintained a neutral rating for Apellis Pharmaceuticals (APLS, Financial). This steady rating comes amidst a recent announcement where the firm decided to raise its price target for the company's stock.
The price target was adjusted from $23.00 to $24.00, marking a 4.35% increase. This change indicates a positive outlook on the future valuation of Apellis Pharmaceuticals (APLS, Financial), as reflected in the refined price target.
The APLS stock is traded on the NASDAQ exchange, and this update by B of A Securities is a noteworthy development for investors tracking the performance of Apellis Pharmaceuticals.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 19 analysts, the average target price for Apellis Pharmaceuticals Inc (APLS, Financial) is $35.53 with a high estimate of $60.00 and a low estimate of $18.00. The average target implies an upside of 83.60% from the current price of $19.35. More detailed estimate data can be found on the Apellis Pharmaceuticals Inc (APLS) Forecast page.
Based on the consensus recommendation from 22 brokerage firms, Apellis Pharmaceuticals Inc's (APLS, Financial) average brokerage recommendation is currently 2.2, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Apellis Pharmaceuticals Inc (APLS, Financial) in one year is $191.17, suggesting a upside of 887.96% from the current price of $19.35. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Apellis Pharmaceuticals Inc (APLS) Summary page.
